» Articles » PMID: 2900690

Characterization of IL-2-induced Murine Cells Which Exhibit ADCC Activity

Overview
Journal Cell Immunol
Publisher Elsevier
Date 1988 Sep 1
PMID 2900690
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The incubation of murine splenocytes in recombinant interleukin 2 (IL-2) gives rise to both lymphokine-activated killer (LAK) cells capable of lysing fresh tumor cells and cells capable of mediating antibody-dependent cellular cytotoxicity (ADCC) in the presence of anti-H2 allosera. A similarity between these two IL-2-induced cell populations was found. The precursors of the cells mediating these activities were shown to be ASGM1 positive, Thy 1 negative, and radiosensitive. Cells taken from the spleen, thymus, and bone marrow were able to mediate ADCC after culture in IL-2. The effector cell was either Thy 1 positive or negative and was less affected by anti-Thy 1 plus C' treatment than cells which mediated LAK activity. In addition ADCC was exhibited in IL-2-cultured splenocytes from various murine strains and correlated with their LAK activity with one exception. While IL-2-cultured C57BL/6 splenocytes exhibited LAK activity similar to that of C3H LAK cells, no ADCC activity could be demonstrated in C57BL/6 cells. Study of the difference in the ability of these two strains to mediate ADCC revealed that IL-2-induced FcR+ cells in C3H thymocytes, but not in C57BL/6 thymocytes. Based on FACS analysis and on the radiosensitivity of the induction of both FcR+ cells and ADCC, it was suggested that IL-2 was expanding a small FcR+ cell population rather than inducing an increase in FcR density on the cell surface. The relationship between the IL-2-induced ADCC mediator and other IL-2-induced cells, as well as ADCC effector cells, and the possible implications of the results for the in vivo therapy of cancer based on ADCC are discussed.

Citing Articles

Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking.

Ramakrishna V, Eisenthal A, Skornick Y, Shinitzky M Cancer Immunol Immunother. 1993; 36(5):293-9.

PMID: 8477415 PMC: 11038729. DOI: 10.1007/BF01741167.


Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.

Vuist W, Visseren M, Otsen M, Bos K, Vyth-Dreese F, Figdor C Cancer Immunol Immunother. 1993; 36(3):163-70.

PMID: 8439976 PMC: 11038052. DOI: 10.1007/BF01741087.


Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.

Eisenthal A, Kashtan H, Rabau M, Ramakrishna V, Chaitchik S, Skornick Y Cancer Immunol Immunother. 1993; 36(2):101-7.

PMID: 8425207 PMC: 11038442. DOI: 10.1007/BF01754409.


Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.

Eisenthal A, Skornick Y, Merimsky O, Hirsch R, Zakut V, Ron I Cancer Immunol Immunother. 1993; 37(4):233-9.

PMID: 8348562 PMC: 11038831. DOI: 10.1007/BF01518516.


Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.

Eisenthal A Cancer Immunol Immunother. 1990; 31(6):342-8.

PMID: 2386979 PMC: 11038655. DOI: 10.1007/BF01741405.